| Bioactivity | AGI-14100 is a metabolically stable and orally available mIDH1 inhibitor (IC50=6 nM). The pharmacochemical optimization of AGI-14100 is aimed at eliminating hPXR activation, resulting in the final drug candidate AG-120. AG-120 can be used in the study of cancers carrying IDH1 mutations. The discovery and development of AGI-14100 can be used for further studies of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors[1]. |
| CAS | 1448346-43-7 |
| Formula | C29H22ClF4N5O3 |
| Molar Mass | 599.96 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Popovici-Muller J, et al. Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers[J]. ACS medicinal chemistry letters, 2018, 9(4): 300-305. |
AGI-14100
CAS: 1448346-43-7 F: C29H22ClF4N5O3 W: 599.96
AGI-14100 is a metabolically stable and orally available mIDH1 inhibitor (IC50=6 nM). The pharmacochemical optimization
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.